Trial · NCT03054337
Adverse events900
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 900
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Viral upper respiratory tract infection | Infections and infestations | Primary Efficacy Period: 150 mg Vadadustat | 0 | 12 | |
| other | Viral upper respiratory tract infection | Infections and infestations | Primary Efficacy Period: 300 mg Vadadustat | 1 | 12 | |
| other | Viral upper respiratory tract infection | Infections and infestations | Primary Efficacy Period: 600 mg Vadadustat | 0 | 13 | |
| other | Viral upper respiratory tract infection | Infections and infestations | Primary Efficacy Period: Placebo Matched to 150 mg Vadadustat | 0 | 5 | |
| other | Viral upper respiratory tract infection | Infections and infestations | Primary Efficacy Period: Placebo Matched to 300 mg Vadadustat | 1 | 4 | |
| other | Viral upper respiratory tract infection | Infections and infestations | Primary Efficacy Period: Placebo Matched to 600 mg Vadadustat | 0 | 5 | |
| other | Viral upper respiratory tract infection | Infections and infestations | Dose Adjustment and Maintenance: 150 mg Vadadustat | 1 | 12 | |
| other | Viral upper respiratory tract infection | Infections and infestations | Dose Adjustment and Maintenance: 300 mg Vadadustat | 1 | 12 | |
| other | Viral upper respiratory tract infection | Infections and infestations | Dose Adjustment and Maintenance: 600 mg Vadadustat | 1 | 13 | |
| other | Viral upper respiratory tract infection | Infections and infestations | Dose Adjustment and Maintenance: Placebo to 150 mg Vadadustat | 1 | 5 | |
| other | Viral upper respiratory tract infection | Infections and infestations | Dose Adjustment and Maintenance: Placebo to 300 mg Vadadustat | 0 | 4 | |
| other | Viral upper respiratory tract infection | Infections and infestations | Dose Adjustment and Maintenance: Placebo to 600 mg Vadadustat | 0 | 5 | |
| other | Hypertension | Vascular disorders | Primary Efficacy Period: 150 mg Vadadustat | 0 | 12 | |
| other | Hypertension | Vascular disorders | Primary Efficacy Period: 300 mg Vadadustat | 3 | 12 | |
| other | Hypertension | Vascular disorders | Primary Efficacy Period: 600 mg Vadadustat | 2 | 13 | |
| other | Hypertension | Vascular disorders | Primary Efficacy Period: Placebo Matched to 150 mg Vadadustat | 0 | 5 | |
| other | Hypertension | Vascular disorders | Primary Efficacy Period: Placebo Matched to 300 mg Vadadustat | 0 | 4 | |
| other | Hypertension | Vascular disorders | Primary Efficacy Period: Placebo Matched to 600 mg Vadadustat | 0 | 5 | |
| other | Hypertension | Vascular disorders | Dose Adjustment and Maintenance: 150 mg Vadadustat | 0 | 12 | |
| other | Hypertension | Vascular disorders | Dose Adjustment and Maintenance: 300 mg Vadadustat | 0 | 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03054337/events